Carl Eriksson

Articles in journals

• Karlqvist, S. , Sachs, M. C. , Eriksson, C. , Cao, Y. , Montgomery, S. , Ludvigsson, J. F. , Olén, O. , Halfvarson, J. & et al. (2024). Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease: Results From Nationwide Swedish Registers.  American Journal of Gastroenterology. [BibTeX]
• Thunberg, J. , Grännö, O. , Bergemalm, D. , Eriksson, C. , Visuri, I. , Eberhardson, M. & Halfvarson, J. (2024). Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels.  Scandinavian Journal of Gastroenterology, 59 (2), 150-155. [BibTeX]
• Eriksson, C. , Sun, J. , Bryder, M. , Bröms, G. , Everhov, Å. H. , Forss, A. , Jernberg, T. , Ludvigsson, J. F. & et al. (2024). Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study.  Alimentary Pharmacology and Therapeutics, 59 (9), 1122-1133. [BibTeX]
• Lamichhane, N. , Melas, N. , Bergqvist, V. , Ekholm, N. , Olén, O. , Ludvigsson, J. F. , Hjortswang, H. , Marsal, J. & et al. (2024). Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease.  Digestive Diseases and Sciences, 69 (6), 2175-2183. [BibTeX]
• Shrestha, S. , Brand, J. S. , Osooli, M. , Eriksson, C. , Schoultz, I. , Askling, J. , Jess, T. , Montgomery, S. & et al. (2024). Spondyloarthritis in first-degree relatives and spouses of patients with inflammatory bowel disease: A nationwide population-based cohort study from Sweden.  Journal of Crohn's & Colitis, 18 (9), 1371-1380. [BibTeX]
• Visuri, I. , Eriksson, C. , Karlqvist, S. , Lykiardopoulos, B. , Karlén, P. , Grip, O. , Söderman, C. , Almer, S. & et al. (2023). Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study.  Therapeutic Advances in Gastroenterology, 16. [BibTeX]
• Wallhuss, A. , Ottosson, J. , Cao, Y. , Andersson, E. , Bergemalm, D. , Eriksson, C. , Olén, O. , Szabo, E. & et al. (2023). Outcomes of bariatric surgery for patients with prevalent inflammatory bowel disease: A nationwide registry-based cohort study.  Surgery, 174 (2), 144-151. [BibTeX]
• Eriksson, C. , Söderling, J. , Karlqvist, S. , Bröms, G. , Everhov, Å. H. , Bergemalm, D. , Ludvigsson, J. F. , Olén, O. & et al. (2023). Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease.  Digestive Diseases and Sciences, 68 (7), 3119-3128. [BibTeX]
• Yanai, H. , Eriksson, C. & Aharoni Golan, M. (2022). Endoscopic Postoperative Recurrence In Crohn's Disease After Curative Ileocecal Resection With Early Prophylaxis By Anti-Tnf, Vedolizumab Or Ustekinumab: A Real-World Multicenter European Study.  Journal of Crohn's & Colitis, 16 (12), 1882-1892. [BibTeX]
• Phillips, F. , Verstockt, B. , Sladek, M. , de Boer, N. , Katsanos, K. , Karmiris, K. , Albshesh, A. , Erikson, C. & et al. (2022). Orofacial Granulomatosis associated with Crohn's Disease: a multi-centre case series.  Journal of Crohn's & Colitis, 16 (3), 430-435. [BibTeX]
• Thunberg, J. , Björkqvist, O. , Hedin, C. R. H. , Forss, A. , Söderman, C. , Bergemalm, D. , Olén, O. , Hjortswang, H. & et al. (2022). Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality register.  United European Gastroenterology journal, 10 (7), 631-639. [BibTeX]
• Eriksson, C. , Visuri, I. , Vigren, L. , Nilsson, L. , Kärnell, A. , Hjortswang, H. , Bergemalm, D. , Almer, S. & et al. (2021). Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG.  Scandinavian Journal of Gastroenterology, 56 (11), 1304-1311. [BibTeX]
• Rundquist, S. , Sachs, M. C. , Eriksson, C. , Olén, O. , Montgomery, S. & Halfvarson, J. (2021). Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.  Alimentary Pharmacology and Therapeutics, 53 (4), 471-483. [BibTeX]
• Rundquist, S. , Sachs, M. C. , Eriksson, C. , Olén, O. , Montgomery, S. & Halfvarson, J. (2021). Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply.  Alimentary Pharmacology and Therapeutics, 53 (5), 642-643. [BibTeX]
• Albshesh, A. , Taylor, J. , Savarino, E. V. , Truyens, M. , Armuzzi, A. , Ribaldone, D. G. , Shitrit, A. B. , Fibelman, M. & et al. (2021). Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study.  Journal of Clinical Medicine, 10 (13). [BibTeX]
• Rundquist, S. , Sachs, M. C. , Eriksson, C. , Olén, O. , Montgomery, S. & Halfvarson, J. (2021). Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply.  Alimentary Pharmacology and Therapeutics, 53 (9), 1046-1047. [BibTeX]
• Visuri, I. , Eriksson, C. , Olén, O. , Cao, Y. , Mårdberg, E. , Grip, O. , Gustavsson, A. , Hjortswang, H. & et al. (2021). Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register.  Alimentary Pharmacology and Therapeutics, 54 (7), 931-943. [BibTeX]
• Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Udumyan, R. , Karlén, P. , Grip, O. , Söderman, C. , Almer, S. & et al. (2021). Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study.  Therapeutic Advances in Gastroenterology, 14. [BibTeX]
• Bergemalm, D. , Andersson, E. , Hultdin, J. , Eriksson, C. , Rush, S. T. , Kalla, R. , Adams, A. T. , Keita, Å. V. & et al. (2021). Systemic Inflammation in Preclinical Ulcerative Colitis.  Gastroenterology, 161 (5), 1526-1539.e9. [BibTeX]
• Wildeman, P. , Tevell, S. , Eriksson, C. , Lagos, A. C. , Söderquist, B. & Stenmark, B. (2020). Genomic characterization and outcome of prosthetic joint infections caused by Staphylococcus aureus.  Scientific Reports, 10 (1). [BibTeX]
• Burisch, J. , Eriksson, C. , Halfvarson, J. & Odes, S. (2020). Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.  The Lancet Gastroenterology & Hepatology, 5 (5), 454-464. [BibTeX]
• Moens, A. , van der Woude, C. J. , Julsgaard, M. , Humblet, E. , Sheridan, J. , Baumgart, D. C. , De Saint-Joseph, C. G. , Nancey, S. & et al. (2020). Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.  Alimentary Pharmacology and Therapeutics, 51 (1), 129-138. [BibTeX]
• Shrestha, S. , Olén, O. , Eriksson, C. , Everhov, Å. H. , Myrelid, P. , Visuri, I. , Ludvigsson, J. F. , Schoultz, I. & et al. (2020). The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register.  Scandinavian Journal of Gastroenterology, 55 (4), 430-435. [BibTeX]
• Burisch, J. , Chetcuti Zammit, S. , Ellul, P. , Turcan, S. , Duricova, D. , Bortlik, M. , Winther Andersen, K. , Andersen, V. & et al. (2019). Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: an Epi-IBD study.  Journal of Gastroenterology and Hepatology, 34 (6), 996-1003. [BibTeX]
• Eriksson, C. , Rundquist, S. , Cao, Y. , Montgomery, S. & Halfvarson, J. (2019). Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study.  Gut, 68 (4), 623-632. [BibTeX]
• Burisch, J. , Kiudelis, G. , Kupcinskas, L. , Kievit, H. A. L. , Andersen, K. W. , Andersen, V. , Salupere, R. , Pedersen, N. & et al. (2019). Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study.  Gut, 68 (3), 423-433. [BibTeX]
• Burisch, J. , Katsanos, K. H. , Christodoulou, D. K. , Barros, L. , Magro, F. , Pedersen, N. , Kjeldsen, J. , Vegh, Z. & et al. (2019). Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study.  Journal of Crohn's & Colitis, 13 (2), 198-208. [BibTeX]
• Rundquist, S. , Eriksson, C. , Nilsson, L. , Angelison, L. , Jäghult, S. , Björk, J. , Grip, O. , Hjortswang, H. & et al. (2018). Clinical effectiveness of golimumab in Crohn's disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).  Scandinavian Journal of Gastroenterology, 53 (10-11), 1257-1263. [BibTeX]
• Eriksson, C. , Henriksson, I. , Brus, O. , Zhulina, Y. , Nyhlin, N. , Tysk, C. , Montgomery, S. & Halfvarson, J. (2018). Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population-based cohort study.  Alimentary Pharmacology and Therapeutics, 48 (6), 638-645. [BibTeX]
• Eriksson, C. , Rundquist, S. , Lykiardopoulos, B. , Karlén, P. , Grip, O. , Söderman, C. , Almer, S. , Hertervig, E. & et al. (2017). A Swedish observational study (SVEAH) on vedolizumab assessing effectiveness and healthcare resource utilization in patients with inflammatory bowel disease.  Journal of Crohn's & Colitis, 11 (Suppl. 1), S262-S263. [BibTeX]
• Eriksson, C. , Cao, Y. , Rundquist, S. , Zhulina, Y. , Henriksson, I. , Montgomery, S. & Halfvarson, J. (2017). Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Orebro, Sweden, 1963-2010.  Alimentary Pharmacology and Therapeutics, 46 (8), 748-757. [BibTeX]
• Eriksson, C. , Cao, Y. , Rundquist, S. , Zhulina, Y. , Henriksson, I. , Montgomery, S. & Halfvarson, J. (2017). Editorial: do thiopurines and biologics decrease the risk of colectomy? Authors' reply.  Alimentary Pharmacology and Therapeutics, 46 (9), 897-898. [BibTeX]
• Eriksson, C. , Marsal, J. , Bergemalm, D. , Vigren, L. , Björk, J. , Eberhardson, M. , Karling, P. , Söderman, C. & et al. (2017). Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).  Scandinavian Journal of Gastroenterology, 52 (6-7), 722-729. [BibTeX]

Articles, reviews/surveys

• Eriksson, C. , Gustavsson, A. , Kronvall, T. & Tysk, C. (2011). Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature.  Journal of Gastrointestinal and Liver Diseases, 20 (1), 77-80. [BibTeX]

Conference papers

• Karlqvist, S. , Sachs, M. , Eriksson, C. , Cao, Y. , Montgomery, S. , Ludvigsson, J. F. , Olén, O. & Halfvarson, J. (2024). Comparative risk of serious infection with vedolizumab vs anti-TNF in Inflammatory Bowel Disease: Results from nationwide Swedish registers. In:  Journal of Crohn's & Colitis. Paper presented at 19th Congress of ECCO, Stockholm, Sweden, February 21-24, 2024. (pp. I1291-I1293). Oxford University Press. [BibTeX]
• Bröms, G. , Forss, A. , Eriksson, J. , Linder, M. , Eriksson, C. , Askling, J. , Halfvarson, J. , Ludvigsson, J. F. & et al. (2024). Disease characteristics at time of diagnosis of adult onset inflammatory bowel disease and the risk of venous thromboembolism in the modern era - A Swedish nationwide cohort study 2007-2021. In:  Journal of Crohn's & Colitis. Paper presented at 19th Congress of ECCO, Stockholm, Sweden, February 21-24, 2024. (pp. I1945-I1947). Oxford University Press. [BibTeX]
• Grännö, O. , Salomon, B. , Lindqvist, C. M. , Hedin, C. R. H. , Carlson, M. , Dannenberg, K. , Andersson, E. , Söderholm, J. D. & et al. (2024). Preclinical protein signatures in blood predict Crohn's disease and Ulcerative colitis several years before the diagnosis. In:  Journal of Crohn's & Colitis. Paper presented at 9th Congress of ECCO, Stockholm, Sweden, February 21-24, 2024. (pp. I660-I661). Oxford University Press. [BibTeX]
• Salomon, B. , Carlson, M. , Bergemalm, D. , Hedin, C. R. H. , Söderholm, J. D. , Keita, Å. V. , Carsten, A. , Grip, O. & et al. (2024). Prognostic potential of mucosal proteins in Ulcerative Colitis. In:  Journal of Crohn's & Colitis. Paper presented at 16th Congress of ECCO - European Crohn’s and Colitis Organisation (ECCO'21), (Virtual congress), July 2-3, 8-10, 2021. (pp. I544-I545). Oxford University Press. [BibTeX]
• Bazov, I. , Kruse, R. , Bergemalm, D. , Eriksson, C. , Hedin, C. R. , Carlson, M. , van Nieuwenhoven, M. , Keita, Å. V. & et al. (2023). A novel serum protein signature as biomarker for Inflammatory Bowel Disease: A diagnostic performance and prediction modelling study using data from two independent inception cohorts. In:  Journal of Crohn's & Colitis. Paper presented at 18th Congress of ECCO Copenhagen, Denmark, March 1-4, 2023. (pp. I314-I315). Oxford University Press. [BibTeX]
• Wewer, M. D. , Salupere, R. , Kievit, H. A. L. , Nielsen, K. R. , Midjord, J. , Domislovic, V. , Krznarić, Ž. , Pedersen, N. & et al. (2023). Disease course of Crohn's disease during the first ten years following diagnosis in a prospective European population-based inception cohort - the Epi-IBD cohort. In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
• Wewer, M. D. , Salupere, R. , Kievit, H. A. L. , Nielsen, K. R. , Midjord, J. , Domislovic, V. , Krznarić, Ž. , Pedersen, N. & et al. (2023). Disease course of Ulcerative Colitis during the first ten years following diagnosis in a prospective European population-based inception cohort - the Epi-IBD cohort. In:  Journal of Crohn's & Colitis. Paper presented at 18th Congress of ECCO, Copenhagen, Denmark, March 1-4, 2023. (pp. 994-995). Oxford University Press. [BibTeX]
• Thunberg, J. , Björkqvist, O. , Olén, O. , Ludvigsson, J. F. , Eriksson, C. & Halfvarson, J. (2021). Drug survival and remission rates in ustekinumab treated ulcerative colitis: Results from the Swedish Inflammatory Bowel Disease register (SWIBREG). In:  Journal of Crohn's & Colitis. Paper presented at 16th Congress of ECCO - European Crohn’s and Colitis Organisation (ECCO'21), (Virtual congress), July 2-3, 8-10, 2021. (pp. S317-S317). Oxford University Press. [BibTeX]
• Rundquist, S. , Sachs, M. , Eriksson, C. , Olén, O. , Montgomery, S. & Halfvarson, J. (2020). Effectiveness of anti-TNF vs. vedolizumab as a second biologic in IBD: results from national Swedish registers. In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
• Phillips, F. , Verstockt, B. , Sladek, M. , de Boer, N. , Katsanos, K. , Karmiris, K. , Albshesh, A. , Eriksson, C. & et al. (2020). Orofacial granulomatosis in Crohn's disease: an ECCO CONFER multi-centre case series. In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
• Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Udumyan, R. , Karlén, P. , Grip, O. , Söderman, C. , Almer, S. & et al. (2020). Real-world effectiveness of vedolizumab in ulcerative colitis: Week 52 results from the Swedish multi-centre, prospective, observational SVEAH UC study. In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
• Visuri, I. , Eriksson, C. , Mårdberg, E. , Grip, O. , Gustavsson, A. , Hjortswang, H. , Karling, P. , Montgomery, S. & et al. (2019). Anti-TNF agent drug survival in patients with IBD: real-world comparisons of individual anti-TNF agents based on the Swedish National Quality Registry for IBD (SWIBREG). In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
• Bergemalm, D. , Andersson, E. , Karling, P. , Eriksson, C. , Repsilber, D. , Hultdin, J. , Halfvarson, J. & IBD Character Consortium, . (2019). Markers of systemic inflammation in preclinical ulcerative colitis. In:  United European Gastroenterology journal. Sage Publications. [BibTeX]
• Moens, A. , van der Woude, C. , Julsgaard, M. , Sebastian, S. , Arebi, N. , Alzinaty, M. , Humblet, E. , Kok, K. B. & et al. (2019). Pregnancy outcomes in IBD patients treated with vedolizumab, anti-TNF, or conventional therapy. In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
• Rundquist, S. , Eriksson, C. , Nilsson, L. , Angelison, L. , Jäghult, S. , Björk, J. , Grip, O. , Hjortswang, H. & et al. (2018). Clinical effectiveness of golimumab in Crohn´s disease – an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Paper presented at 26th United European Gastroenterology Week, Vienna, Austria, October 20-24, 2018. [BibTeX]
• Eriksson, C. , Bergemalm, D. , Vigren, L. , Nilsson, L. , Visuri, I. , Hjortswang, H. , Udumyan, R. , Almer, S. & et al. (2018). Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD-GO-SWIBREG. In:  Journal of Crohn's & Colitis. Paper presented at 13th Congress of ECCO – European Crohn’s and Colitis Organisation, Vienna, Austria, February 14-17, 2018. (pp. S409-S410). Oxford University Press. [BibTeX]
• Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Karlen, P. , Grip, O. , Söderman, C. , Almer, S. , Hertervig, E. & et al. (2018). Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn's disease (SVEAH CD). In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
• Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Karlen, P. , Grip, O. , Söderman, C. , Almer, S. , Hertervig, E. & et al. (2018). Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC). In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
• Eriksson, C. , Rundquist, S. , Cao, Y. , Montgomery, S. & Halfvarson, J. (2018). The impact of thiopurine drugs on the natural history and surgical outcome of ulcerative colitis: A cohort study. In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]

Doctoral theses, comprehensive summaries

• Eriksson, C. (2018). Epidemiological and therapeutic aspects of Inflammatory Bowel Disease. (Doctoral dissertation). (Comprehensive summary) Örebro: Örebro University. [BibTeX]

Manuscripts

• Karlqvist, S. , Sachs, M. C. , Eriksson, C. , Cao, Y. , Montgomery, S. , Ludvigsson, J. F. , The SWIBREG Study Group, -. , Olén, O. & et al. Comparative risk of serious infection with vedolizumab vs anti-TNF in inflammatory bowel disease : results from nationwide Swedish registers. [BibTeX]
• Visuri, I. , Dannenberg, K. , Salomon, B. , Ling Lundström, M. , Bergemalm, D. , Eriksson, C. , Lindqvist, C. M. , Keita, Å. V. & et al. Correlations of clinical characteristics and serum proteins with drug levels : A multicentre cohort study of patients with inflammatory bowel disease starting biologics. [BibTeX]
• Wildeman, P. , Tevell, S. , Eriksson, C. , Campillay Lagos, A. , Söderquist, B. & Stenmark, B. Genomic characterization and outcome of prosthetic joint infections caused by Staphylococcus aureus. [BibTeX]
• Carstens, A. , Björkqvist, O. , Lindqvist, C. M. , Rangel, I. , Repsilber, D. , Eriksson, C. , Bergemalm, D. , Bresso, F. & et al. Gut microbiota associated with treatment outcome to biological treatment in inflammatory bowel disease. [BibTeX]
• Eriksson, C. , Henriksson, I. , Brus, O. , Zhulina, Y. , Nyhlin, N. , Tysk, C. & Montgomery, S. Incidence, prevalence, and clinical outcome of anaemia in inflammatory bowel disease : A population-based cohort study. [BibTeX]
• Shrestha, S. , Cao, Y. , Voghera, S. , Eriksson, C. , Schoultz, I. , Jess, T. , Ludvigsson, J. F. , Montgomery, S. & et al. The risk of extraintestinal manifestations before and after colectomy in patients with ulcerative colitis. [BibTeX]